Applied Therapeutics said on Monday it received a warning letter limited to a trial studying its genetic disease drug, after ...
Applied Therapeutics' New Drug Application for a rare metabolic disease was rejected by the Food and Drug Administration, ...
Applied Therapeutics stock (APLT) was down 75% early Friday on news the FDA had declined to approve its drug govorestat, ...
Applied Therapeutics said on Wednesday that the U.S. FDA declined to approve its drug to treat galactosemia, a rare genetic ...
The pharma company's shares are getting crushed after regulators decline to green light a drug to treat a rare disease.
Applied Therapeutics faces challenges after FDA rejection, but future opportunities exist. Learn why APLT stock could recover ...
Leerink Partners analyst Joseph Schwartz has maintained their bullish stance on APLT stock, giving a Buy rating on November 29.Don't Miss our ...
After extending its review period to evaluate additional submissions, the FDA ultimately denied Applied Therapeutics’ ...
The FDA has rejected Applied Therapeutics’ attempt to win approval on the strength of a failed phase 3 trial, triggering a 75 ...
Applied Therapeutics ( APLT, Financials) announced that the U.S. Food and Drug Administration issued a Complete Response ...
NEW YORK, NY / ACCESSWIRE / December 3, 2024 / Levi & Korsinsky notifies investors that it has commenced an investigation of Applied ...
The US Food and Drug Administration has declined to approve Applied Therapeutics’ govorestat for classic galactosemia.